GREATER CHINA Sector Macau Gaming: Apr 25 GGR beat expectations; May Day Golden Week visitor arrivals expected to grow 4% yoy. Results ASMPT (522 HK/BUY/HK$52.20/Target: HK$68.00): 1Q25: Earnings disappoint; mainstream tools recovering in 2025 but visibility remains low. Maintain BUY. China Tourism Group Duty Free (601888 CH/BUY/Rmb63.40/Target: Rmb70.80): 1Q25: Core net profit down 16% yoy; sequential improvement in Hainan duty-free sales. Ganfeng Lithium (1772 HK/BUY/HK$18.94/Target: HK$30.00)...
The tone at BH’s 1Q25 analyst meeting was negative. Management still does not expect a rebound in hospital revenue as a result of the earthquake in Mar 25. The drop in revenue intensity in 1Q25 could become a concern if it becomes a recurring trend. Despite the positive development in Saudi Arabia and Bangladesh, we are less optimistic on BH as it lacks a substantial catalyst to improve its earnings. Downgrade to HOLD. Target price: Bt178.00.
KEY HIGHLIGHTS Sector Property 1Q25 earnings under pressure; recovery outlook remains uncertain. Update Asset World Corporation (AWC TB/BUY/Bt2.20/Target: Bt3.30) Expect strong earnings growth in 1Q25. Bumrungrad Hospital (BH TB/HOLD/Bt168.50/Target: Bt178.00) Less optimistic on foreign patient numbers. Downgrade to HOLD. Siam Cement (SCC TB/HOLD/Bt160.00/Target: Bt160.00) Timeline for the LSP project to resume operations remains uncertain.
BH reported a net profit of Bt1.73b (-12.6% yoy, -8.9% qoq) in 1Q25, which is in line with our and consensus estimates. The high base last year and the earlier timing of Ramadan this year caused top-line to drop by 6.1% yoy. Growth in revenue from Thai patients was weak at 1.3% yoy and was not sufficient to compensate for the shortfall in foreign patient revenue. We are more optimistic about BH’s 2Q25 outlook as the impact from Ramadan was already realised in 1Q25. Maintain BUY. Target pric...
KEY HIGHLIGHTS Sector Banking 1Q25: Results beat; banks prioritise less on loan growth. Downgrade to MARKET WEIGHT. Results Bumrungrad Hospital (BH TB/BUY/Bt169.00/Target: Bt232.00) 1Q25: Weak results in line with expectations. Update Thai Foods Group (TFG TB/BUY/Bt5.05/Target: Bt6.70) Expect record-high earnings in 1Q25 and 2Q25. Thanachart Capital (TCAP TB/HOLD/Bt47.00/Target: Bt48....
GREATER CHINA Results Aier Eye Hospital Group (300015 CH/BUY/Rmb12.72/Target: Rmb17.80) 2024: Satisfactory results; expects strong recovery in 2025. Upgrade to BUY. Ningbo Tuopu Group Co (601689 CH/BUY/Rmb50.96/Target: Rmb83.00) 4Q24: Earnings up 38.5% yoy, in line. Maintain BUY with target price unchanged at Rmb83.00. TAL Educational Group (TAL US/BUY/US$9.36/Target: US$14.00) 4QFY25: Earnings miss amid ramped-up investments in AI-powered learning. INDONESIA Sector Telecommun...
We expect BH to report a net profit of Bt1.7b in 1Q25 (-13.2% yoy, -9.4% qoq). Top-line should be weak at Bt6.1b (-6.5% yoy, -5.6% qoq) due to the high base last year and the earlier timing of Ramadan this year. As a result, the expected decrease in Middle Eastern patient volume should also lead to a yoy margin contraction. We expect the 2Q25 outlook to improve, as a yoy growth will come off a more normalised base in 2Q24. Maintain BUY. Target price: Bt232.00.
KEY HIGHLIGHTS Results Bangkok Bank (BBL TB/HOLD/Bt146.50/Target: Bt154.00) 1Q25: Results beat expectations; investment gain boosted the bottom line. TISCO Financial Group (TISCO TB/HOLD/Bt100.00/Target: Bt94.00) 1Q25: Results in line; revises down 2025 credit cost target to 100bp. Update Bumrungrad Hospital (BH TB/BUY/Bt168.00/Target: Bt232.00) Expect weak 1Q25 earnings due to margin pressure.
We attended BH’s 4Q24 analyst meeting and the tone was neutral. The strong growth of Thai patients in 4Q24 was attributable to the health checkup season. There have been favourable developments in Middle Eastern countries like Kuwait and Saudi Arabia but a definite timeline is still lacking. We believe that earnings growth in 1Q25 will be challenging due to the shortfall in Kuwait. However, we expect to see a gradual improvement from 2Q25 onwards. Maintain BUY. Target price: Bt232.00.
Update Bumrungrad Hospital (BH TB/BUY/Bt195.50/Target: Bt232.00) Outlook for foreign patients remains under observation. Origin Property (ORI TB/HOLD/Bt2.68/Target: Bt2.90) Conservative 2025 business plan focusing on financial stability. Stecon Group (STECON TB/BUY/Bt5.40/Target: Bt6.50) Overhang clears; earnings recovery in sight
GREATER CHINA Economics Highlights From The NPC: A comprehensive response to economic challenges. Update Cathay Pacific Airways (293 HK/HOLD/HK$10.76/Target: HK$11.30): Cathay’s stellar 2024 earnings performance is unlikely to be sustainable in the long run, but a potential beat of street estimates may still provide a near-term trading opportunity. INDONESIA Update Bank Rakyat Indonesia (BBRI IJ/BUY/Rp3,840/Target: Rp4,500): Spike in CoC in 1Q25; focus on cleaning up loans. MALAYSIA Sector Tec...
BH reported a net profit of Bt1.9b in 4Q24 (+10.6% yoy, -2.7% qoq), above our expectations but in line with consensus’. The strong earnings were mainly contributed by the utilisation of tax benefit in the quarter. Top-line came in at Bt6.5b, down slightly yoy due to the continuous drop in foreign patient revenue, partly offset by the strong growth of Thai patients. We expect to see slight growth in 1Q25 with a mixed outlook. Maintain BUY. Target price: Bt232.00.
Results Amata Corporation (AMATA TB/BUY/Bt23.90/Target: Bt35.00) 4Q24: Net income misses expectations but still robust yoy and qoq. AP Thailand (AP TB/BUY/Bt8.70/Target: Bt11.30) 4Q24: Earnings in line; aggressive strategy for 2025. Bumrungrad Hospital (BH TB/BUY/Bt183.50/Target: Bt232.00) 4Q24: Strong 4Q24 earnings attributable to tax benefit. Hana Microelectronics (HANA TB/HOLD/Bt20.10/Target: Bt22.00) 4Q24: Net loss from high impairment. Indorama Ventures (IVL TB/BUY/Bt19.30/Target: Bt30.00)...
GREATER CHINA Sector Automobile Weekly: PV sales picked up wow while the wait-and-see sentiment continues. Upgrade Li Auto and XPeng from HOLD to BUY and raise target price to HK$156.00 and HK$110.00 respectively. Maintain MARKET WEIGHT on the sector. Top BUYs: Geely, CATL, Fuyao and Desay. Results BeiGene (6160 HK/BUY/HK$161.60/Target: HK$220.00) 2024: Results beat; targets operating profit...
BH should report a net profit of Bt1.7b in 4Q24 (-1.3% yoy, -13.1% qoq). The earnings should remain weak as the top-line is expected to be pressured by the weak international patient outlook. Although BH should be fairly immune to copayment, the weak outlook for top-line growth is likely to persist. We expect the 1Q25 outlook to remain weak, as Ramadan this year will fall entirely in 1Q25, negatively impacting BH's earnings. Maintain BUY. Target price: Bt232.00.
KEY HIGHLIGHTS Update Bumrungrad Hospital (BH TB/BUY/Bt175.50/Target: Bt232.00) Weak 4Q24 earnings expected. Central Plaza Hotel (CENTEL TB/BUY/Bt28.00/Target: Bt33.00) Reaching a turning point; upgrade to BUY. Central Pattana (CPN TB/BUY/Bt52.25/Target: Bt79.30) Expect 4Q24 earnings to be pressured by SG&A, but 2024 is set to deliver a record profit.
GREATER CHINA Sector Automobile Weekly: PV sales stay low, BYD to equip all EVs with DiPilot ADAS. Upgrade BYD to BUY. Maintain MARKET WEIGHT on the sector. Top BUYs: Geely, CATL, Fuyao and Desay. Update AAC Technologies (2018 HK/HOLD/HK$46.55/ Target: HK$48.00) 2024 profit alert – earnings set to beat expectations. Maintain HOLD. The United Laboratories International (3933 HK/HOLD/HK$12.42/Target: H...
GREATER CHINA Economics PMI A strong rebound for non-manufacturing PMI. Sector Macau Gaming Dec 24 GGR below expectations; expect 2025 GGR to recover to 82% of 2019’s level. INDONESIA Update Mitra Keluarga Karyasehat (MIKA IJ/BUY/Rp2,540/Target: Rp3,300) Expect a double-digit earnings growth in 2025 MALAYSIA Sector Heal...
A director at Bumrungrad Hospital Public Company Limited sold 100,000 shares at 199.000THB and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
BH reported a net profit of Bt1.96b in 3Q24 (+0.0% yoy, +1.2% qoq) which disappointed the market due to lower-than-expected revenue. Revenue from both Thai and foreign patients declined yoy. We believe that in the long term, BH still has strong fundamentals as construction of its new hospital in Phuket has already started and capacity expansion at the main campus is underway. Maintain BUY. Target price: Bt303.00.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.